Baxter gets a nudge downward

Goldman Sachs removes Baxter International (BAX) from its Conviction List and lowers its PT from $83 to $77 but maintains its Buy recommendation. Since the firm added BAX to its Americas CL in August it is off 7.7% versus the S&P 500's 8.5% gain.

Analyst David Roman cites a higher risk profile due to heightened competition in the plasma business.

Investors appear unconcerned. Shares are up a fraction in early trading.

From other sites
Comments (1)
  • DavidBaird
    , contributor
    Comments (225) | Send Message
    My thought is that Goldman's price target of $83 might have been a little optimistic to begin with.....
    17 Mar 2014, 07:31 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs